Hostname: page-component-857557d7f7-h6shg Total loading time: 0 Render date: 2025-11-27T02:40:49.363Z Has data issue: false hasContentIssue false
  • English
  • Français

Paliperidone Palmitate Long-Acting Injection in Schizophrenic Patients: Improved of Negative Symtons and Metabolic Rates. 6 Years of follow up

Published online by Cambridge University Press:  26 August 2025

E. S. Gisbert
E. S. Gisbert*
Affiliation:
PSYCHIATRY, HOSPITAL UNIVERSITARIO INFANTA SOFIA, SAN SEBASTIAN DE LOS REYES, Spain

Abstract

Core share and HTML view are not available for this content. However, as you have access to this content, a full PDF is available via the ‘Save PDF’ action button.
Introduction

PALIPERIDONE PALMITATE can improved the metabolic rates better than oral paliperidone. The negative symtoms and metabolic syndrome are a very frecuent phemomena with hard treatment.

Objectives

Find the differences in the improving of negative symtoms and the metabolic rates in patients with change of neuroleptic (oral to paliperidone palmitate injection).

Methods

MATERIAL AND METHODS: Observational longitudinal study during 72 months. We incluided all the patients with the diagnosis of schizophrenia, in which we done a change from oral neurolepic to Palmitate of Paliperidone and age of 18 years o more. There was a control group with paliperidone oral.

We used SANSS and CGI-Scale for negative symtoms and metabolic rates (weight, IMC, Glucose, Colestherol, TG and prolactin) and abdominal perimeter.

Results

40 patients was included and only 4 refused. 56% are male. Average age 41.22 years. 24% has metabolic disease, 29% with axis IV disease and 30% with toxic substances Average dosis of palmate of paliperidone 105 mg/28 days.

The reason of change to injection was: No response 38% to oral neuroleptic treatment and side effects 28%. Rest patients wish.

Metabolic rates improved: Less in weight, IMC, Glucose, Colestherol, TG and prolactin and abdominal perimeter. These improved in the 6 years of study

The SANSS scale improved, All of them were stadistical significative (p<0,05) and CGI scale results improved.

Conclusions

CONCLUSIONS The change from oral neuroleptic to palmitate of paliperidone improved metabolic rates and abdominal perimeter.

Also improved SANSS and CGI Scale.

The palmitate of paliperidone is useful in schizophrenic patients and with less incidence of metabolic side efects and improved of negative symptoms.

Disclosure of Interest

None Declared

Information

Type
Abstract
Information
European Psychiatry , Volume 68 , Special Issue S1: Abstracts of the 33rd European Congress of Psychiatry , April 2025 , pp. S249
Creative Commons
Creative Common License - CCCreative Common License - BY
This is an Open Access article, distributed under the terms of the Creative Commons Attribution licence (https://creativecommons.org/licenses/by/4.0/), which permits unrestricted re-use, distribution, and reproduction in any medium, provided the original work is properly cited.
Copyright
© The Author(s), 2025. Published by Cambridge University Press on behalf of European Psychiatric Association
Submit a response

Comments

No Comments have been published for this article.